The Biospecimen Extraction Resource (BER) is a centralized laboratory for standardized, high-quality, reasonably-priced DMA and RNA extraction from various sources. The BER performs PCR-based analysis of these nucleic acids including pyrosequencing for genotyping of single nucleotide polymorphisms and for detection of CpG island methylation. In addition, the BER consults with non-laboratory-based investigators to help them accomplish their laboratory-based goals related to the facility. The BER is located in the newlyconstructed Basic Science Research Building (BSRB). The BER uses state-of-the-art instrumentation including the Autopure LS automated DMA extraction machine and the PSQ pyrosequencer. The BER has an 8-member oversight committee. A website provides information about services, guidelines for preparing samples for DMA extraction, and other procedures performed by the facility, as well as forms to be completed when requesting service. In the current grant period, the BER was used by 35 different investigators from 17 programs with 98% of usage coming from investigators having peer-reviewed funding. Most of the DMA extractions are from human peripheral blood leukocytes or saliva. An increase of over 400% has been seen over the past year compared to those extracted in 2002. The source of funds for the proposed operating budget of the BER for year 33 (July 1, 2008-June 30, 2009) is 14% from TexGen, 53% from user fees, and 34% from the CCSG. Future plans include continued expansion to large projects such as TexGen, the """"""""LBJ Patient History Database-Serum/DNA Bank"""""""" and the """"""""Repository of Tissue and Blood on Patients in the Cancer Prevention Center.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310870
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$79,349
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Jabbour, Elias; DerSarkissian, Maral; Duh, Mei Sheng et al. (2018) Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18:257-265
Pataer, Apar; Shao, Ruping; Correa, Arlene M et al. (2018) Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7:2405-2414
Short, Nicholas J; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59:813-820
Shank, Brandon R; Deaver, Melissa; Baker, Angela et al. (2018) Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients. J Oncol Pharm Pract 24:365-370
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103

Showing the most recent 10 out of 12418 publications